Educational, research-use-only content. This article summarizes published scientific literature for informational purposes only and is not medical advice. The compounds discussed are supplied strictly for in-vitro laboratory research and are not approved for human or veterinary use.
GHK-Cu is one of the most extensively studied small peptides in dermatological and tissue-science research. Here is a grounded look at what the published, PubMed-indexed literature has examined — and where the evidence is strongest and weakest.
What is GHK-Cu?
GHK is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine). It binds copper(II) ions with an affinity similar to copper’s transport site on albumin, forming the GHK-Cu complex. Levels of GHK in human plasma are reported to decline with age, which is part of why it became a focus of skin- and repair-related research (Pickart, 2008).
Tissue-remodeling and collagen research
A widely cited review compiled laboratory findings indicating that GHK and GHK-Cu can influence a range of remodeling-related processes in experimental systems — including increased synthesis of collagen, elastin, and other matrix proteins, and proliferation of fibroblasts and keratinocytes (Pickart, 2008). It is important to note this review was authored by the peptide’s original discoverer and aggregates many model systems.
Dermal fibroblast cell studies
In cultured normal human dermal fibroblasts, GHK and its copper complex were reported to modulate IGF-2-dependent secretion of TGF-β1, a signaling molecule involved in wound-repair and scar biology (Gruchlik et al., 2014). This is cell-culture (in-vitro) research into mechanism, not a demonstration of a clinical outcome., 2014).
The limits of the current evidence
- Much foundational work originates with one researcher (L. Pickart), and a large share of the literature is mechanistic or cell-based.
- Context matters. A great deal of GHK-Cu study sits in cosmetic-science and in-vitro settings; findings there do not transfer automatically to other uses.
- Not an approved drug. GHK-Cu has not been evaluated by the U.S. Food and Drug Administration for safety or effectiveness as a drug, and it is not approved for human use.
References
According to PubMed:
- Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008. doi:10.1163/156856208784909435
- Gruchlik A, Chodurek E, Dzierzewicz Z. Effect of Gly-His-Lys and its copper complex on TGF-β secretion in normal human dermal fibroblasts. Acta Pol Pharm. 2014. PMID:25745767
- Badenhorst T, Svirskis D, Wu Z. Physicochemical characterization of native glycyl-L-histidyl-L-lysine tripeptide for wound healing and anti-aging. Pharm Dev Technol. 2014. doi:10.3109/10837450.2014.979944
